|
Prof George Canellos talks about the key research that has emerged from the 2010 ASH meeting in Florida. One trial of note compared the Stanford V treatment regimen with ABVD for patients with advanced Hodgkin’s lymphoma and revealed that Stanford V was not superior to ABVD. Prof Canellos explains why this lack of superiority and the adverse effects associated with Stanford V's obligate radiotherapy indicate that ABVD is a more attractive treatment option. A second trial which avoids the use of radiotherapy involved patients with primary mediastinal large B-cell lymphoma. This trial demonstrated that treating patients with an intensified chemotherapy regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) and ICE (ifosfamide, carboplatin and etoposide), whilst only irradiating patients when it was necessary was associated with an extremely high survival rate. Prof Canellos concludes by discussing two trials demonstrating the effectiveness of targeting CD30 protein cells with the antibody SGN-35 (brentuximab vedotin) and one looking at treating post-transplant relapsed or refractory Hodgkin lymphoma patients with the histone deacetylase inhibitor panobinostat (LBH-589).
|
Video Length: 0
Date Found: February 21, 2011
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|